Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Real-Time Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down5.650 -0.090 (-1.568%)

15/10/2019 11:25

{I-bank focus}UBS upgrades Luye Pharma (02186) to HK$7.8

[ET Net News Agency, 15 October 2019] UBS Global Research lifted slightly its target
price for Luye Pharma Group (02186) to HK$7.8 from HK$7.66 and upgraded its rating to
"buy" from "neutral" on low valuation.
The research house fine-tuned its 2019-21 EPS (diluted) forecasts by 4-7%
With differentiated labels from Nab-paclitaxel and room for normal paclitaxel and
docetaxel (P&D) replacement, UBS thinks Lipusu (LPS) revenue growth could remain steady in
2019-20 and stay around Rmb2.3bn by 2024, despite competition from Nab-paclitaxel.
UBS expects the launch of new drugs in 2020-22 to offset a potential LPS decline over
the longer run. (KL)

Remark: Real time quote last updated: 13/12/2019 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2019 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.